Overview

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Diego
Treatments:
Pembrolizumab
Tadalafil